Lepor Herbert
Department of Urology, New York University School of Medicine New York, NY.
Rev Urol. 2009 Fall;11(Suppl 1):S9-S13.
The medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating alpha-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both alpha-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of alpha-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.
良性前列腺增生（BPH）的医学治疗始于20世纪70年代初。在这个时期，首次报道了针对临床BPH男性的α受体阻滞剂和雄激素剥夺疗法的临床试验。服用α受体阻滞剂和雄激素剥夺疗法后临床BPH得到改善这一观察结果支持了不断发展的范式，即临床BPH是由动态和静态途径导致的。在过去几十年中，用于治疗BPH的α受体阻滞剂的发展受到了旨在简化给药并提高耐受性同时保持其有效性的创新的影响。
